Table 1.
Baseline characteristics of subjects.
| B-B-B (n = 15) |
B-C-B (n = 5) |
C-C-C (n = 9) |
C-C-B (n = 8) |
p-Value | |
|---|---|---|---|---|---|
| Age (Years) | 53 (26–76) | 47 (22–58) | 58 (31–64) | 58.5 (27–70) | 0.54 |
| Sex | 0.888 | ||||
| Male | 7 (46.7%) | 2 (40%) | 5 (55.6%) | 3 (37.5%) | |
| Female | 8 (53.3%) | 3 (60%) | 4 (44.4%) | 5 (62.5%) | |
| Comorbidities | 4 (26.7%) | 1 (20%) | 5 (55.6%) | 2 (25%) | 0.395 |
| Date Post-3rd Dose (Days) | 14 (3–39) | 5 (5–7) | 14 (5–32) | 8 (4–29) | 0.2443 |
Data are median age (range) or n (%); B-B-B: participants primed with 2 doses of BNT162b2 and 1 booster dose of BNT162b2; B-C-B: participants primed with BNT162b2 (first dose) and CoronaVac (second dose), and received 1 booster dose of BNT162b2; C-C-C: participants primed with 2 doses of CoronaVac and received 1 booster dose of CoronaVac; C-C-B: participants primed with 2 doses of CoronaVac and received 1 booster dose of BNT162b2; Comorbidities: hypertension (HT), ischemic heart disease (IHD), diabetes mellitus (DM), stroke, chronic heart failure (CHF), malignancy, asthma, chronic obstructive pulmonary disease (COPD) and thyroid diseases. Median number of days post-third-dose vaccination (range).